COVID-19 among fit patients with CLL treated with venetoclax-based combinations

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch

Bibliographic citation
In: Leukemia ; 34 (2020), 8. - S. 2225-2229. - ISSN 0887-6924. - eISSN 1476-5551

Keyword
Infektionskrankheit

Event
Veröffentlichung
(where)
Ulm
(who)
Universität Ulm
(when)
2020
Creator
Fürstenau, Moritz
Langerbeins, Petra
De Silva, Nisha
Fink, Anna Maria
Robrecht, Sandra
Tresckow, Julia von
Simon, Florian
Hohloch, Karin
Droogendijk, Jolanda
van der Klift, Marjolein
van der Spek, Ellen
Illmer, Thomas
Schöttker, Björn
Fischer, Kirsten
Wendtner, Clemens M.
Tausch, Eugen
Stilgenbauer, Stephan
Niemann, Carsten U.
Gregor, Michael
Kater, Arnon P.
Hallek, Michael
Eichhorst, Barbara

DOI
10.18725/OPARU-51223
URN
urn:nbn:de:bsz:289-oparu-51299-1
Rights
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:36 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Fürstenau, Moritz
  • Langerbeins, Petra
  • De Silva, Nisha
  • Fink, Anna Maria
  • Robrecht, Sandra
  • Tresckow, Julia von
  • Simon, Florian
  • Hohloch, Karin
  • Droogendijk, Jolanda
  • van der Klift, Marjolein
  • van der Spek, Ellen
  • Illmer, Thomas
  • Schöttker, Björn
  • Fischer, Kirsten
  • Wendtner, Clemens M.
  • Tausch, Eugen
  • Stilgenbauer, Stephan
  • Niemann, Carsten U.
  • Gregor, Michael
  • Kater, Arnon P.
  • Hallek, Michael
  • Eichhorst, Barbara
  • Universität Ulm

Time of origin

  • 2020

Other Objects (12)

Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement

Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement

Venetoclax bei der chronischen lymphatischen Leukämie (CLL)

Fallstudiensammlung

Venetoclax bei der chronischen lymphatischen Leukämie (CLL)

BCL-2-Inhibition mit Venetoclax (Venclyxto) : neue gezielte Therapieoption bei chronischer lymphatischer Leukämie (CLL)

BCL-2-Inhibition mit Venetoclax (Venclyxto) : neue gezielte Therapieoption bei chronischer lymphatischer Leukämie (CLL)

Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma

Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma

Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines

Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines

Nowcasting Canadian GDP with density combinations

Arbeitspapier

Nowcasting Canadian GDP with density combinations

Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia

Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia

Three allele combinations associated with Multiple Sclerosis

Three allele combinations associated with Multiple Sclerosis

Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies

Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia

Venetoclax combined with FLAG-IDA in refractory or relapsed acute myeloid leukemia

Related objects